New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy.

Auteurs : Andreozzi F, Massaro F, Wittnebel S, Spilleboudt C, Lewalle P, Salaroli A
Jaar : 2022
Journal : Int J Mol Sci
Volume : 23

Acute Promyelocytic Leukaemia (Apl) In The Elderly Patient.

Auteurs : Salaroli A, Spilleboudt C, Lewalle P, Wittnebel S
Jaar : 2021
Journal : Belgian J Hematology
Volume : 12(8)
Pagina's : 332–7

SARS-CoV-2 infection in hematological patients during allogenic stem cell transplantation: A double case report.

Auteurs : Van Uytvanck A, Wittnebel S, Meuleman N, Loizidou A, Salengros JC, Spilleboudt C
Jaar : 2021
Journal : Clin Case Rep
Volume : 9
Pagina's : e04439

Hepatosplenic T-cell lymphoma: treatment challenges.

Auteurs : Bron D, de Leval L, Michiels S, Wittnebel S
Jaar : 2021
Journal : Curr Opin Oncol
Volume : 33
Pagina's : 406-411

Critically ill cancer patient's resuscitation: a Belgian/French societies' consensus conference.

Auteurs : Meert AP, Wittnebel S, Holbrechts S, Toffart AC, Lafitte JJ, Piagnerelli M, Lemaitre F, Peyrony O, Calvel L, Lemaitre J, Canet E, Demoule A, Darmon M, Sculier JP, Voigt L, Lemiale V, Pène F, Schnell D, Lengline E, Berghmans T, Fiévet L, Jungels C, Wang X, Bold I, Pistone A, Salaroli A, Grigoriu B, Benoit D
Jaar : 2021
Journal : Intensive Care Med
Volume : 47
Pagina's : 1063-1077

Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients.

Auteurs : Baron F, Efficace F, Cannella L, Willemze R, Vignetti M, Muus P, Marie JP, Ferrero D, Fazi P, La Sala E, Bourhis JH, Fabbiano F, Bosi A, Sborgia M, Martinelli G, Wittnebel S, Trisolini S, Petti MC, Halkes CJM, van der Velden WJFM, de Witte T, Amadori S, Zittoun RA, Suciu S
Jaar : 2020
Journal : Haematologica
Volume : 105
Pagina's : e13-e16

Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).

Auteurs : Rahmé R, Ades L, Thomas X, Guerci-Bresler A, Pigneux A, Vey N, Raffoux E, Castaigne S, Spertini O, Wittnebel S, Marolleau JP, Damaj G, Bordessoule D, Lejeune J, Chevret S, Fenaux P
Jaar : 2018
Journal : Haematologica
Volume : 103
Pagina's : e519-e521

Low dose clofarabine in combination with a standard remission induction in patients 18-60 years with previously untreated intermediate and bad risk acute myeloid leukemia or high risk myelodysplastic syndrome: combined Phase I/II results of the EORTC

Auteurs : Selleslag D, Suciu S, Meloni G, Muus P, Halkes CJ, Venditti A, Ramadan SM, Pruijt H, Meert L, Vignetti M, Marie JP, Wittnebel S, de Witte T, Amadori S, Willemze R, Baron F
Jaar : 2017
Journal : Haematologica
Volume : 102(2)
Pagina's : e47-51

Retrospective chart review of hospitalizations and costs associated with the treatment of adults with Philadelphia-negative B-cell relapsed or refractory acute lymphoblastic leukemia in Belgium.

Auteurs : Maertens J, Graux C, Breems D, Havelange V, Wittnebel S, Strens D, Hoefkens C
Jaar : 2017
Journal : Acta Clin Belg
Volume : 72(6)
Pagina's : 429-433

Risk-adapted transplant strategies for high-risk Hodgkin lymphoma: are we there?

Auteurs : Lewalle P, Wittnebel S
Jaar : 2016
Journal : Curr Opin Oncol
Volume : 28
Pagina's : 390-7

Belgium recommendations for the management of acute promyelocytic leukaemia

Auteurs : Wittnebel S
Jaar : 2016
Journal : Belgian J Hematology
Volume : 7
Pagina's : 224-8